|
1
|
Dietz U, Dauer C and Lambertz H: Combining
short stent implantation and drug-eluting stenting for routine use
yields a low restenosis rate. Exp Clin Cardiol. 11:294–297.
2006.PubMed/NCBI
|
|
2
|
Gurvitch R, Lefkovits J, Warren RJ, Duffy
SJ, Clark DJ, Eccleston D, Yan BP, Reid C, Brennan A,
Andrianopoulos N, et al: Clinical outcomes of drug-eluting stent
use in patients with ST elevation myocardial infarction. Int J
Cardiol. 143:283–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ghattas A, Shantsila E and Lip GY:
Antithrombotic therapy after percutaneous coronary intervention in
anticoagulated patients: A fine balance between thrombosis and
bleeding. Ther Adv Cardiovasc Dis. 5:5–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stone GW, Lansky AJ, Pocock SJ, Gersh BJ,
Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie
BR, et al: HORIZONS-AMI Trial Investigators: Paclitaxel-eluting
stents versus bare-metal stents in acute myocardial infarction. N
Engl J Med. 360:1946–1959. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oduncu V, Erkol A, Tanboğa IH and Kırma C:
Late bare metal stent thrombosis. Türk Kardiyol Dern Arş - Arch
Turk Soc Cardiol. 38:422–425. 2010.
|
|
6
|
Heldman AW, Cheng L, Jenkins GM, Heller
PF, Kim DW, Ware M Jr, Nater C, Hruban RH, Rezai B, Abella BS, et
al: Paclitaxel stent coating inhibits neointimal hyperplasia at 4
weeks in a porcine model of coronary restenosis. Circulation.
103:2289–2295. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang X and Zhao HB: Effects of paclitaxel
hirudin complex on proliferation and migration of vascular smooth
muscle cells and endothelial cells of rabbits. Chin J Evid Based
Cardiovasc Med. 1:65–69. 2009.
|
|
8
|
Wang X and Zhao HB: Effects of paclitaxel
hirudin complex on the growth of rabbit vascular endothelial cells
and smooth muscle cells (unpublished PhD thesis). Shanxi Medical
University. 2011.
|
|
9
|
Li HM and Wang X: Influence of hirudin on
growth of in vitro human coronary artery smooth muscle cells and
human coronary artery endothelial cells. Chin J Evid Based
Cardiovasc Med. 7:792–794,797. 2015.
|
|
10
|
Li HM and Wang X: Influence of
lipopolysaccharide on growth of in vitro human coronary artery
smooth muscle cells: An investigation on establishing in-stent
restenosis inflammatory cells model. Chin J Evid Based Cardiovasc
Med. 8:29–33. 2016.
|
|
11
|
Li HM and Wang X: Influence of
lipoposaccharide (LPS) on expressions of inflammatory factors of in
vitro human coronary artery smooth muscle cells (HCASMC): An
investigation on establishing in-stent restenosis inflammation cell
model. Chin J Evid Based Cardiovasc Med. 8:297–301. 2016.
|
|
12
|
Jensen LO, Thayssen P, Christiansen EH,
Maeng M, Ravkilde J, Hansen KN, Hansen HS, Krusell L, Kaltoft A,
Tilsted HH, et al: SORT OUT IV Investigators: Safety and efficacy
of everolimus-versus sirolimus-eluting stents: 5-year results from
SORT OUT IV. J Am Coll Cardiol. 67:751–762. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Montone RA, Hoole SP and West NE:
Prehospital ticagrelor in ST-segment elevation myocardial
infarction. N Engl J Med. 371:2338–2339. 2014.PubMed/NCBI
|
|
14
|
van Hinsbergh VW: Endothelium - role in
regulation of coagulation and inflammation. Semin Immunopathol.
34:93–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Puricel S, Cuculi F, Weissner M,
Schmermund A, Jamshidi P, Nyffenegger T, Binder H, Eggebrecht H,
Münzel T, Cook S, et al: Bioresorbable coronary scaffold
thrombosis: Multicenter comprehensive analysis of clinical
presentation, mechanisms, and predictors. J Am Coll Cardiol.
67:921–931. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yvon AM, Wadsworth P and Jordan MA: Taxol
suppresses dynamics of individual microtubules in living human
tumor cells. Mol Biol Cell. 10:947–959. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xin S, Yu F, Yang C and Hao X: Inhibition
of paclitaxel against neuroglioma cells u251 growth and its
mechanism. Afr J Tradit Complement Altern Med. 14:174–178. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ellis SG, Kereiakes DJ, Metzger DC, Caputo
RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, et
al: ABSORB III Investigators: Everolimus-eluting bioresorbable
scaffolds for coronary artery disease. N Engl J Med. 373:1905–1915.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gerber RT, Latib A, Ielasi A, Cosgrave J,
Qasim A, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I,
et al: Defining a new standard for IVUS optimized drug eluting
stent implantation: The PRAVIO study. Catheter Cardiovasc Interv.
74:348–356. 2009.PubMed/NCBI
|
|
20
|
Hong MK, Mintz GS, Lee CW, Park DW, Choi
BR, Park KH, Kim YH, Cheong SS, Song JK, Kim JJ, et al:
Intravascular ultrasound predictors of angiographic restenosis
after sirolimus-eluting stent implantation. Eur Heart J.
27:1305–1310. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Joner M, Finn AV, Farb A, Mont EK,
Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK and Virmani R:
Pathology of drug-eluting stents in humans: Delayed healing and
late thrombotic risk. J Am Coll Cardiol. 48:193–202. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee CW, Kang SJ, Park DW, Lee SH, Kim YH,
Kim JJ, Park SW, Mintz GS and Park SJ: Intravascular ultrasound
findings in patients with very late stent thrombosis after either
drug-eluting or bare-metal stent implantation. J Am Coll Cardiol.
55:1936–1942. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Morice MC, Serruys PW, Sousa JE, Fajadet
J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P,
Guagliumi G, et al: RAVEL Study Group. Randomized study with the
sirolimus-coated Bx Velocity Balloon-Expandable Stent in the
treatment of patients with de novo native coronary artery lesions:
A randomized comparison of a sirolimus-eluting stent with a
standard stent for coronary revascularization. N Engl J Med.
346:1773–1780. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moses JW, Leon MB, Popma JJ, Fitzgerald
PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams
DO, Teirstein PS, et al: SIRIUS Investigators: Sirolimus-eluting
stents versus standard stents in patients with stenosis in a native
coronary artery. N Engl J Med. 349:1315–1323. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moses JW, Dangas G, Mehran R and Mintz GS:
Drug-eluting stents in the real world: How intravascular ultrasound
can improve clinical outcome. Am J Cardiol. 102 Suppl:24J–28J.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pfisterer M, Brunner-La Rocca HP, Buser
PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F,
Osswald S and Kaiser C; BASKET-LATE Investigators, : Late clinical
events after clopidogrel discontinuation may limit the benefit of
drug-eluting stents: An observational study of drug-eluting versus
bare-metal stents. J Am Coll Cardiol. 48:2584–2591. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Warkentin TE: Bivalent direct thrombin
inhibitors: Hirudin and bivalirudin. Best Pract Res Clin Haematol.
17:105–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He L, Vicente CP, Westrick RJ, Eitzman DT
and Tollefsen DM: Heparin cofactor II inhibits arterial thrombosis
after endothelial injury. J Clin Invest. 109:213–219. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lincoff AM, Bittl JA, Kleiman NS,
Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL,
Bachinsky WB, Tift-Mann J III, et al: REPLACE-1 Investigators:
Comparison of bivalirudin versus heparin during percutaneous
coronary intervention (the Randomized Evaluation of PCI Linking
Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J
Cardiol. 93:1092–1096. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Section of Interventional Cardiology of
Chinese Society of Cardiology of Chinese Medical Association;
Specialty Committee on Prevention and Treatment of Thrombosis of
Chinese College of Cardiovascular Physicians; Editorial Board of
Chinese Journal of Cardiology: Chinese guidelines for percutaneous
coronary intervention (2016). Zhonghua Xin Xue Guan Bing Za Zhi.
44:382–400. 2016.(In Chinese). PubMed/NCBI
|
|
31
|
Thome LM, Gimple LW, Bachhuber BG,
McNamara CA, Ragosta M, Gertz SD, Powers ER, Owens GK, Humphries JE
and Sarembock IJ: Early plus delayed hirudin reduces restenosis in
the atherosclerotic rabbit more than early administration alone:
Potential implications for dosing of antithrombin agents.
Circulation. 98:2301–2306. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gerdes C, Faber-Steinfeld V, Yalkinoglu O
and Wohlfeil S: Comparison of the effects of the thrombin inhibitor
r-hirudin in four animal models of neointima formation after
arterial injury. Arterioscler Thromb Vasc Biol. 16:1306–1311. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Alt E, Haehnel I, Beilharz C, Prietzel K,
Preter D, Stemberger A, Fliedner T, Erhardt W and Schömig A:
Inhibition of neointima formation after experimental coronary
artery stenting: A new biodegradable stent coating releasing
hirudin and the prostacyclin analogue iloprost. Circulation.
101:1453–1458. 2000. View Article : Google Scholar : PubMed/NCBI
|
